Jacob Mathew
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jacob Mathew has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Allen Fong
Department of Internal Medicine, US Army Brooke Army Medical Center, Fort Sam Houston, Texas, USA
1 shared publication- Faisal Mahfooz
Internal Medicine, Parkview Medical Center, Pueblo, Colorado, USA
1 shared publication Kourtney Aylor
Internal Medicine, Parkview Medical Center, Pueblo, Colorado, USA
1 shared publicationMegan Reichmuth
Pulmonary and Critical Care Medicine, Parkview Medical Center, Pueblo, Colorado, USA
1 shared publicationMichael R Povlow
Department of Radiology, US Army Brooke Army Medical Center, Fort Sam Houston, Texas, USA
1 shared publication
Latest Publications
- 18 January 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (1) , e235663
Extending our understanding of exenatide: a rare case of angio-oedema
Exenatide is a subcutaneous injectable glucagon-like peptide 1 receptor agonist that has been approved by the Federal Drug Administration for the treatment of type 2 diabetes mellitus. While side effects such as nausea, vomiting and local hypersensitivity reactions are more commonly described, angio-oedema has never been previously reported in the literature. We present the case of a 67-year-old woman who presented to the emergency department with acute-onset tongue swelling, difficulty breathing, dizziness and diffuse itching which began shortly after receiving her first dose of intramuscular extended release (ER) exenatide. This case aims to raise awareness of the potential adverse effect of angio-oedema secondary to exenatide ER and serves as a reminder to clinicians to discuss possible adverse effects of medications and early recognition of symptoms which would prompt further medical attention.
- 18 January 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (1) , e235663
Extending our understanding of exenatide: a rare case of angio-oedema
Exenatide is a subcutaneous injectable glucagon-like peptide 1 receptor agonist that has been approved by the Federal Drug Administration for the treatment of type 2 diabetes mellitus. While side effects such as nausea, vomiting and local hypersensitivity reactions are more commonly described, angio-oedema has never been previously reported in the literature. We present the case of a 67-year-old woman who presented to the emergency department with acute-onset tongue swelling, difficulty breathing, dizziness and diffuse itching which began shortly after receiving her first dose of intramuscular extended release (ER) exenatide. This case aims to raise awareness of the potential adverse effect of angio-oedema secondary to exenatide ER and serves as a reminder to clinicians to discuss possible adverse effects of medications and early recognition of symptoms which would prompt further medical attention.
- 6 June 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (6) , e230317
Get off my back! Inferior vena cava filter erosion into the lumbar spine
- 6 June 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (6) , e230317
Get off my back! Inferior vena cava filter erosion into the lumbar spine
- 1 November 2018
- Published by BMJ in BMJ Case Reports
- Vol. 11 (1) , e226711
Clostridium difficile colitis in the setting of subacute thyroiditis: the chicken or the egg
Subacutethyroiditis is a self-limited inflammatory condition commonly of viral aetiology, that manifests through phases of thyroid hormone changes over a 6–8 month period. A 24-year-old active duty military man, undergoing treatment for recurrent Clostridiumdifficile infection, presented for clinical evaluation and was found to have a thyroid stimulating hormone level of 0.003 mg/dL. Further labs revealed a normal T4, elevated T3 at 5.0 pg/mL and elevated C reactive protein at 3.69 mg/L. The patient was followed with monthly labs and the abnormal thyroid stimulating hormone and triiodothyronine levels resolved after the completion of his C. difficile treatment. While subacute thyroiditis has historically been due to viral causes, rarely do we see this condition associated with an intestinal bacterial source.
- 1 November 2018
- Published by BMJ in BMJ Case Reports
- Vol. 11 (1) , e226711
Clostridium difficile colitis in the setting of subacute thyroiditis: the chicken or the egg
Subacutethyroiditis is a self-limited inflammatory condition commonly of viral aetiology, that manifests through phases of thyroid hormone changes over a 6–8 month period. A 24-year-old active duty military man, undergoing treatment for recurrent Clostridiumdifficile infection, presented for clinical evaluation and was found to have a thyroid stimulating hormone level of 0.003 mg/dL. Further labs revealed a normal T4, elevated T3 at 5.0 pg/mL and elevated C reactive protein at 3.69 mg/L. The patient was followed with monthly labs and the abnormal thyroid stimulating hormone and triiodothyronine levels resolved after the completion of his C. difficile treatment. While subacute thyroiditis has historically been due to viral causes, rarely do we see this condition associated with an intestinal bacterial source.